Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAdagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAcurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAcrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenZymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZurn Elkay Water Solutions Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevia PBC has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZura Bio Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZumiez Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZoetis reported FY2025 revenue of $9.47 billion and Q1 2026 revenue of $2.26 billion, with the official record tying the thesis to companion-animal demand, livestock cycles, product innovation, inventory quality, debt and cash conversion.
OpenZTO Express reported 2025 revenue of CNY 49.10 billion, operating income of CNY 10.47 billion and operating cash flow of CNY 11.97 billion. The thesis turns on China parcel volume, pricing, network efficiency, cash conversion and ADR governance risk.
OpenYY Group Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZenta Group Company Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenAiRWA Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZentek Ltd. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open